JP2018008949A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2018008949A5 JP2018008949A5 JP2017130334A JP2017130334A JP2018008949A5 JP 2018008949 A5 JP2018008949 A5 JP 2018008949A5 JP 2017130334 A JP2017130334 A JP 2017130334A JP 2017130334 A JP2017130334 A JP 2017130334A JP 2018008949 A5 JP2018008949 A5 JP 2018008949A5
- Authority
- JP
- Japan
- Prior art keywords
- seq
- residues
- cdr
- chain variable
- variable region
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003446 ligand Substances 0.000 claims description 26
- 230000027455 binding Effects 0.000 claims description 20
- 239000000427 antigen Substances 0.000 claims description 16
- 108091007433 antigens Proteins 0.000 claims description 16
- 102000036639 antigens Human genes 0.000 claims description 16
- 206010028980 Neoplasm Diseases 0.000 claims description 12
- 102100033942 Ephrin-A4 Human genes 0.000 claims description 7
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 7
- 101100171806 Homo sapiens EFNA4 gene Proteins 0.000 claims description 6
- 108010043938 Ephrin-A4 Proteins 0.000 claims description 4
- 210000000130 stem cell Anatomy 0.000 claims description 3
- 230000008685 targeting Effects 0.000 claims description 3
- 231100000599 cytotoxic agent Toxicity 0.000 claims description 2
- 239000012634 fragment Substances 0.000 claims 14
- 230000001613 neoplastic effect Effects 0.000 claims 4
- NFGXHKASABOEEW-UHFFFAOYSA-N 1-methylethyl 11-methoxy-3,7,11-trimethyl-2,4-dodecadienoate Chemical compound COC(C)(C)CCCC(C)CC=CC(C)=CC(=O)OC(C)C NFGXHKASABOEEW-UHFFFAOYSA-N 0.000 claims 2
- 208000019691 hematopoietic and lymphoid cell neoplasm Diseases 0.000 claims 2
- 230000003463 hyperproliferative effect Effects 0.000 claims 2
- 206010006187 Breast cancer Diseases 0.000 claims 1
- 208000026310 Breast neoplasm Diseases 0.000 claims 1
- 206010009944 Colon cancer Diseases 0.000 claims 1
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims 1
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims 1
- 206010058467 Lung neoplasm malignant Diseases 0.000 claims 1
- 206010033128 Ovarian cancer Diseases 0.000 claims 1
- 206010061535 Ovarian neoplasm Diseases 0.000 claims 1
- 208000029742 colonic neoplasm Diseases 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 239000002254 cytotoxic agent Substances 0.000 claims 1
- 230000000779 depleting effect Effects 0.000 claims 1
- 229940127121 immunoconjugate Drugs 0.000 claims 1
- 208000032839 leukemia Diseases 0.000 claims 1
- 201000007270 liver cancer Diseases 0.000 claims 1
- 208000014018 liver neoplasm Diseases 0.000 claims 1
- 201000005202 lung cancer Diseases 0.000 claims 1
- 208000020816 lung neoplasm Diseases 0.000 claims 1
- 230000003472 neutralizing effect Effects 0.000 claims 1
- 210000004027 cell Anatomy 0.000 description 25
- 102000012803 ephrin Human genes 0.000 description 16
- 108060002566 ephrin Proteins 0.000 description 16
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 108010047041 Complementarity Determining Regions Proteins 0.000 description 8
- 230000014509 gene expression Effects 0.000 description 8
- 102000050554 Eph Family Receptors Human genes 0.000 description 7
- 108091008815 Eph receptors Proteins 0.000 description 7
- 238000004458 analytical method Methods 0.000 description 6
- 208000001333 Colorectal Neoplasms Diseases 0.000 description 5
- 125000003275 alpha amino acid group Chemical group 0.000 description 5
- 150000007523 nucleic acids Chemical group 0.000 description 5
- 210000004881 tumor cell Anatomy 0.000 description 5
- 102000020086 Ephrin-A1 Human genes 0.000 description 4
- 101000925259 Homo sapiens Ephrin-A4 Proteins 0.000 description 4
- 108010029485 Protein Isoforms Proteins 0.000 description 4
- 102000001708 Protein Isoforms Human genes 0.000 description 4
- 230000015861 cell surface binding Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 231100001221 nontumorigenic Toxicity 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 108020003175 receptors Proteins 0.000 description 4
- 102000005962 receptors Human genes 0.000 description 4
- 238000003757 reverse transcription PCR Methods 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 108010043945 Ephrin-A1 Proteins 0.000 description 3
- 101000965523 Homo sapiens Ephrin-A1 Proteins 0.000 description 3
- 150000001413 amino acids Chemical class 0.000 description 3
- 108091028043 Nucleic acid sequence Proteins 0.000 description 2
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 2
- 231100000433 cytotoxic Toxicity 0.000 description 2
- 230000001472 cytotoxic effect Effects 0.000 description 2
- 102000046760 human EFNA1 Human genes 0.000 description 2
- 230000002147 killing effect Effects 0.000 description 2
- 210000004072 lung Anatomy 0.000 description 2
- 238000000034 method Methods 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 201000002528 pancreatic cancer Diseases 0.000 description 2
- 239000003053 toxin Substances 0.000 description 2
- 231100000765 toxin Toxicity 0.000 description 2
- 108700012359 toxins Proteins 0.000 description 2
- 231100000588 tumorigenic Toxicity 0.000 description 2
- 230000000381 tumorigenic effect Effects 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- 101710112752 Cytotoxin Proteins 0.000 description 1
- 108020004414 DNA Proteins 0.000 description 1
- 108010055211 EphA1 Receptor Proteins 0.000 description 1
- 108010055334 EphB2 Receptor Proteins 0.000 description 1
- 102000000075 EphB2 Receptor Human genes 0.000 description 1
- 108010055325 EphB3 Receptor Proteins 0.000 description 1
- 108010055323 EphB4 Receptor Proteins 0.000 description 1
- 102000030797 EphB4 Receptor Human genes 0.000 description 1
- 102100030322 Ephrin type-A receptor 1 Human genes 0.000 description 1
- 102100031982 Ephrin type-B receptor 3 Human genes 0.000 description 1
- 102100033940 Ephrin-A3 Human genes 0.000 description 1
- 108010043940 Ephrin-A3 Proteins 0.000 description 1
- 102000009109 Fc receptors Human genes 0.000 description 1
- 108010087819 Fc receptors Proteins 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 108010084592 Saporins Proteins 0.000 description 1
- 238000012300 Sequence Analysis Methods 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000003556 assay Methods 0.000 description 1
- 238000010256 biochemical assay Methods 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 239000002619 cytotoxin Substances 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 210000004602 germ cell Anatomy 0.000 description 1
- 201000005787 hematologic cancer Diseases 0.000 description 1
- 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
- 230000001900 immune effect Effects 0.000 description 1
- 230000005764 inhibitory process Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- UWKQSNNFCGGAFS-XIFFEERXSA-N irinotecan Chemical compound C1=C2C(CC)=C3CN(C(C4=C([C@@](C(=O)OC4)(O)CC)C=4)=O)C=4C3=NC2=CC=C1OC(=O)N(CC1)CCC1N1CCCCC1 UWKQSNNFCGGAFS-XIFFEERXSA-N 0.000 description 1
- 229960004768 irinotecan Drugs 0.000 description 1
- 238000011330 nucleic acid test Methods 0.000 description 1
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 230000008707 rearrangement Effects 0.000 description 1
- 238000013207 serial dilution Methods 0.000 description 1
- 238000001262 western blot Methods 0.000 description 1
Images
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US42115710P | 2010-12-08 | 2010-12-08 | |
| US61/421,157 | 2010-12-08 | ||
| USPCT/US2011/050451 | 2011-09-02 | ||
| PCT/US2011/050451 WO2012031280A2 (en) | 2010-09-03 | 2011-09-02 | Identification and enrichment of cell subpopulations |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Division JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018008949A JP2018008949A (ja) | 2018-01-18 |
| JP2018008949A5 true JP2018008949A5 (enExample) | 2018-06-14 |
| JP6491701B2 JP6491701B2 (ja) | 2019-04-03 |
Family
ID=46207727
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Expired - Fee Related JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
| JP2017130334A Expired - Fee Related JP6491701B2 (ja) | 2010-12-08 | 2017-07-03 | 新規モジュレーターと使用の方法 |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013543326A Expired - Fee Related JP6279903B2 (ja) | 2010-12-08 | 2011-12-07 | 新規モジュレーターと使用の方法 |
Country Status (18)
| Country | Link |
|---|---|
| US (5) | US20140302034A1 (enExample) |
| EP (2) | EP2648748A1 (enExample) |
| JP (2) | JP6279903B2 (enExample) |
| KR (1) | KR20140031175A (enExample) |
| CN (2) | CN103347538B (enExample) |
| AR (1) | AR084208A1 (enExample) |
| AU (4) | AU2011360938B2 (enExample) |
| BR (2) | BR112013014119A8 (enExample) |
| CA (2) | CA2820885A1 (enExample) |
| CO (1) | CO6821883A2 (enExample) |
| MX (1) | MX356400B (enExample) |
| NZ (3) | NZ611428A (enExample) |
| PE (2) | PE20171143A1 (enExample) |
| PH (2) | PH12013501137A1 (enExample) |
| RU (2) | RU2592672C9 (enExample) |
| SG (3) | SG191081A1 (enExample) |
| TW (2) | TWI585106B (enExample) |
| WO (2) | WO2012118547A1 (enExample) |
Families Citing this family (24)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20140302034A1 (en) | 2010-12-08 | 2014-10-09 | Stem Centrx, Inc. | Novel modulators and methods of use |
| US10323081B2 (en) | 2011-07-06 | 2019-06-18 | Genmag A/S | Modulation of complement-dependent cytotoxicity through modifications of the C-terminus of antibody heavy chains |
| SG11201408161RA (en) | 2012-06-08 | 2015-01-29 | Sutro Biopharma Inc | Antibodies comprising site-specific non-natural amino acid residues, methods of their preparation and methods of their use |
| EP3135690A1 (en) | 2012-06-26 | 2017-03-01 | Sutro Biopharma, Inc. | Modified fc proteins comprising site-specific non-natural amino acid residues, conjugates of the same, methods of their preparation and methods of their use |
| US10047163B2 (en) | 2013-02-08 | 2018-08-14 | Abbvie Stemcentrx Llc | Multispecific constructs |
| US9765116B2 (en) * | 2013-04-18 | 2017-09-19 | Carmel Haifa University Economic Corporation Ltd. | Inhibitors of the Eph-A receptor and uses thereof |
| EP3003368A4 (en) | 2013-05-24 | 2017-05-03 | Biogen MA Inc. | Anti-gpiib/iiia antibodies or uses thereof |
| ES2658039T3 (es) | 2013-07-10 | 2018-03-08 | Sutro Biopharma, Inc. | Anticuerpos que comprenden múltiples residuos de aminoácidos no naturales sitio-específicos, métodos para su preparación y métodos de uso |
| EP3065780A1 (en) * | 2013-11-04 | 2016-09-14 | Pfizer Inc. | Anti-efna4 antibody-drug conjugates |
| US10538591B2 (en) * | 2014-03-10 | 2020-01-21 | The Brigham And Women's Hospital, Inc. | Anti-fibulin-3 antibodies and uses thereof |
| CN105504049B (zh) * | 2014-09-26 | 2019-07-05 | 艾托金生物医药（苏州）有限公司 | 宫颈癌相关的hpv e7蛋白单克隆抗体及其应用 |
| MA40835A (fr) | 2014-10-23 | 2017-08-29 | Biogen Ma Inc | Anticorps anti-gpiib/iiia et leurs utilisations |
| WO2016073845A1 (en) * | 2014-11-07 | 2016-05-12 | Igenica Biotherapeutics, Inc. | Anti-cd39 antibodies and uses thereof |
| CA2929542A1 (en) * | 2015-05-13 | 2016-11-13 | Pfizer Inc. | Treatment with anti-efna4 antibody-drug conjugates |
| US11708413B2 (en) * | 2016-01-27 | 2023-07-25 | Sutro Biopharma, Inc. | Anti-CD74 antibody conjugates, compositions comprising anti-CD74 antibody conjugates and methods of using anti-CD74 antibody conjugates |
| MX2018010445A (es) | 2016-03-01 | 2019-10-17 | Yissum Res Dev Co Of Hebrew Univ Jerusalem Ltd | Anticuerpos especificos del receptor de poliovirus humano (rvp). |
| IL261188B (en) | 2016-03-04 | 2022-08-01 | Jn Biosciences Llc | An anti-tigit antibody that binds to the tigit polypeptide on one or more amino acid residues |
| CN109453382A (zh) * | 2018-11-08 | 2019-03-12 | 浙江大学 | EphrinA1蛋白在制备用于抑制肿瘤细胞侵袭、转移的药物中的应用 |
| WO2020102422A1 (en) * | 2018-11-14 | 2020-05-22 | Arch Oncology, Inc. | THERAPEUTIC SIRPα ANTIBODIES |
| CN114174515A (zh) * | 2019-05-27 | 2022-03-11 | 英属哥伦比亚大学 | tau中的构象特异性表位、其抗体和其相关方法 |
| CR20220611A (es) | 2020-06-02 | 2023-06-07 | Arcus Biosciences Inc | Anticuerpos anti-tigit |
| EP4263600A1 (en) | 2020-12-18 | 2023-10-25 | Century Therapeutics, Inc. | Chimeric antigen receptor systems with adaptable receptor specificity |
| CN113278075B (zh) * | 2021-06-18 | 2021-12-14 | 芜湖森爱驰生物科技有限公司 | 一种炎症检测试剂盒 |
| KR20230142330A (ko) | 2022-03-31 | 2023-10-11 | 주식회사 에스알이엔지 | 일체형 수배전반 열화 방지 시스템 및 이를 이용한 열화 방지 방법 |
Family Cites Families (139)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2413974A1 (fr) | 1978-01-06 | 1979-08-03 | David Bernard | Sechoir pour feuilles imprimees par serigraphie |
| US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
| US4703004A (en) | 1984-01-24 | 1987-10-27 | Immunex Corporation | Synthesis of protein with an identification peptide |
| EP0216846B2 (en) | 1985-04-01 | 1995-04-26 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
| US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
| GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
| US6548640B1 (en) | 1986-03-27 | 2003-04-15 | Btg International Limited | Altered antibodies |
| AU600575B2 (en) | 1987-03-18 | 1990-08-16 | Sb2, Inc. | Altered antibodies |
| GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
| US5336603A (en) | 1987-10-02 | 1994-08-09 | Genentech, Inc. | CD4 adheson variants |
| GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
| US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
| ATE144793T1 (de) | 1989-06-29 | 1996-11-15 | Medarex Inc | Bispezifische reagenzien für die aids-therapie |
| US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
| FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
| WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
| US5959177A (en) | 1989-10-27 | 1999-09-28 | The Scripps Research Institute | Transgenic plants expressing assembled secretory antibodies |
| US6150584A (en) | 1990-01-12 | 2000-11-21 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US6075181A (en) | 1990-01-12 | 2000-06-13 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
| US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
| US5349053A (en) | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
| GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
| AU665190B2 (en) | 1990-07-10 | 1995-12-21 | Cambridge Antibody Technology Limited | Methods for producing members of specific binding pairs |
| US5545806A (en) | 1990-08-29 | 1996-08-13 | Genpharm International, Inc. | Ransgenic non-human animals for producing heterologous antibodies |
| US5661016A (en) | 1990-08-29 | 1997-08-26 | Genpharm International Inc. | Transgenic non-human animals capable of producing heterologous antibodies of various isotypes |
| US5633425A (en) | 1990-08-29 | 1997-05-27 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| US5625126A (en) | 1990-08-29 | 1997-04-29 | Genpharm International, Inc. | Transgenic non-human animals for producing heterologous antibodies |
| KR100272077B1 (ko) | 1990-08-29 | 2000-11-15 | 젠팜인터내셔날,인코포레이티드 | 이종 항체를 생산할 수 있는 전이유전자를 가진 인간이외의 동물 |
| WO1992009690A2 (en) | 1990-12-03 | 1992-06-11 | Genentech, Inc. | Enrichment method for variant proteins with altered binding properties |
| AU643109B2 (en) | 1990-12-14 | 1993-11-04 | Cell Genesys, Inc. | Chimeric chains for receptor-associated signal transduction pathways |
| ATE439435T1 (de) | 1991-03-01 | 2009-08-15 | Dyax Corp | Chimäres protein mit mikroprotein mit zwei oder mehr disulfidbindungen und ausgestaltungen davon |
| DE69233750D1 (de) | 1991-04-10 | 2009-01-02 | Scripps Research Inst | Bibliotheken heterodimerer Rezeptoren mittels Phagemiden |
| WO1992020373A1 (en) | 1991-05-14 | 1992-11-26 | Repligen Corporation | Heteroconjugate antibodies for treatment of hiv infection |
| DE4122599C2 (de) | 1991-07-08 | 1993-11-11 | Deutsches Krebsforsch | Phagemid zum Screenen von Antikörpern |
| US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
| US5667988A (en) | 1992-01-27 | 1997-09-16 | The Scripps Research Institute | Methods for producing antibody libraries using universal or randomized immunoglobulin light chains |
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| FR2686901A1 (fr) | 1992-01-31 | 1993-08-06 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides antithrombotiques, leur preparation et compositions pharmaceutiques les contenant. |
| US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
| ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
| ATE149570T1 (de) | 1992-08-17 | 1997-03-15 | Genentech Inc | Bispezifische immunoadhesine |
| EP0749475A4 (en) | 1992-08-26 | 1997-05-07 | Harvard College | USE OF CYTOKINE IP-10 AS ANTI-TUMOR AGENT |
| ES2091684T3 (es) | 1992-11-13 | 1996-11-01 | Idec Pharma Corp | Aplicacion terapeutica de anticuerpos quimericos y radiomarcados contra el antigeno de diferenciacion restringida de los linfocitos b humanos para el tratamiento del linfoma de las celulas b. |
| US7744877B2 (en) | 1992-11-13 | 2010-06-29 | Biogen Idec Inc. | Expression and use of anti-CD20 Antibodies |
| US5516658A (en) | 1993-08-20 | 1996-05-14 | Immunex Corporation | DNA encoding cytokines that bind the cell surface receptor hek |
| AU3382595A (en) | 1994-07-29 | 1996-03-04 | Smithkline Beecham Corporation | Novel compounds |
| US5919905A (en) * | 1994-10-05 | 1999-07-06 | Immunex Corporation | Cytokine designated LERK-6 |
| US5731168A (en) | 1995-03-01 | 1998-03-24 | Genentech, Inc. | Method for making heteromultimeric polypeptides |
| CA2229043C (en) | 1995-08-18 | 2016-06-07 | Morphosys Gesellschaft Fur Proteinoptimierung Mbh | Protein/(poly)peptide libraries |
| WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
| WO1997034631A1 (en) | 1996-03-18 | 1997-09-25 | Board Of Regents, The University Of Texas System | Immunoglobin-like domains with increased half lives |
| EP0904278A4 (en) | 1996-03-22 | 1999-09-15 | Human Genome Sciences Inc | MOLECULE II INDUCER OF APOPTOSIS |
| AU3251797A (en) | 1996-07-05 | 1998-02-02 | Mount Sinai Hospital Corporation | Oligomerized receptors which affect pathways regulated by transmembrane ligands for elk-related receptor tyrosine kinases |
| US5994076A (en) | 1997-05-21 | 1999-11-30 | Clontech Laboratories, Inc. | Methods of assaying differential expression |
| ES2258817T3 (es) | 1997-05-21 | 2006-09-01 | Biovation Limited | Metodo para la produccion de proteinas no inmunogenas. |
| ES2303358T3 (es) | 1997-11-03 | 2008-08-01 | Human Genome Sciences, Inc. | Vegi, un inhibidor de la angiogenesis y el crecimiento tumoral. |
| JP4460155B2 (ja) | 1997-12-05 | 2010-05-12 | ザ・スクリプス・リサーチ・インステイチユート | マウス抗体のヒト化 |
| US6864227B1 (en) | 1998-04-13 | 2005-03-08 | California Institute Of Technology | Artery-and vein-specific proteins and uses therefor |
| JP4334141B2 (ja) | 1998-04-20 | 2009-09-30 | グリカート バイオテクノロジー アクチェンゲゼルシャフト | 抗体依存性細胞傷害性を改善するための抗体のグリコシル化操作 |
| AUPP674898A0 (en) | 1998-10-27 | 1998-11-19 | Walter And Eliza Hall Institute Of Medical Research, The | A method of treatment |
| ATE352559T1 (de) | 1998-12-08 | 2007-02-15 | Biovation Ltd | Verfahren zur verminderung der immunogenität von proteinen |
| US6737056B1 (en) | 1999-01-15 | 2004-05-18 | Genentech, Inc. | Polypeptide variants with altered effector function |
| BR0008758A (pt) | 1999-01-15 | 2001-12-04 | Genentech Inc | Variantes de polipeptìdeos parentais com funçãoefetora alterada, polipeptìdeos, composição ácidonucleico isolado, vetor, célula hospedeira,método para produzir uma variante depolipeptìdeo, método para o tratamento de umadesordem em mamìferos e método para produziruma região fc variante |
| CA2369292C (en) | 1999-04-09 | 2010-09-21 | Kyowa Hakko Kogyo Co. Ltd. | Method of modulating the activity of functional immune molecules |
| JP2003517816A (ja) | 1999-08-11 | 2003-06-03 | イオス バイオテクノロジー， インコーポレイテッド | 新脈管形成の診断の新規方法、新脈管形成調節因子についてのスクリーニングの組成物および方法 |
| US6927203B1 (en) | 1999-08-17 | 2005-08-09 | Purdue Research Foundation | Treatment of metastatic disease |
| US20050100542A1 (en) * | 1999-10-08 | 2005-05-12 | Young David S. | Cytotoxicity mediation of cells evidencing surface expression of CD44 |
| US6992170B2 (en) * | 1999-10-15 | 2006-01-31 | Curagen Corporation | Polypeptides and polynucleotides homologous to thymosin, ephrin a receptors, and fibromodulin |
| WO2001029246A1 (fr) | 1999-10-19 | 2001-04-26 | Kyowa Hakko Kogyo Co., Ltd. | Procede de production d'un polypeptide |
| WO2001029224A2 (en) | 1999-10-20 | 2001-04-26 | Zymogenetics, Inc. | Granulocyte peptide homolog zgpa1 |
| CA2405550A1 (en) | 2000-04-12 | 2001-10-25 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| AU2001294175A1 (en) | 2000-10-06 | 2002-04-22 | Kyowa Hakko Kogyo Co. Ltd. | Method of purifying antibody |
| US6946292B2 (en) | 2000-10-06 | 2005-09-20 | Kyowa Hakko Kogyo Co., Ltd. | Cells producing antibody compositions with increased antibody dependent cytotoxic activity |
| EA013563B1 (ru) | 2000-10-06 | 2010-06-30 | Киова Хакко Кирин Ко., Лтд. | Трансгенное животное, продуцирующее антитела с измененными углеводными цепями, способ получения антител и содержащее антитела лекарственное средство |
| US7138496B2 (en) | 2002-02-08 | 2006-11-21 | Genetastix Corporation | Human monoclonal antibodies against human CXCR4 |
| PT1355919E (pt) | 2000-12-12 | 2011-03-02 | Medimmune Llc | Moléculas com semivida longa, composições que as contêm e suas utilizações |
| US20040043928A1 (en) | 2001-08-02 | 2004-03-04 | Ramesh Kekuda | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2003064589A2 (en) | 2001-01-23 | 2003-08-07 | Curagen Corporation | Therapeutic polypeptides, nucleic acids encoding same, and methods of use |
| WO2003004057A1 (en) | 2001-07-03 | 2003-01-16 | The Hospital For Sick Children | Ephrin and eph receptor mediated immune modulation |
| ATE430580T1 (de) | 2001-10-25 | 2009-05-15 | Genentech Inc | Glycoprotein-zusammensetzungen |
| EP1453530A2 (en) | 2001-11-09 | 2004-09-08 | Neuronova AB | Method of proliferation in neurogenic regions |
| US7771951B2 (en) | 2001-12-03 | 2010-08-10 | Amgen Fremont Inc. | Antibody categorization based on binding characteristics |
| CA2478239A1 (en) | 2002-03-04 | 2003-09-18 | Medimmune, Inc. | The prevention or treatment of cancer using integrin alphavbeta3 antagonists in combination with other agents |
| EP1575509B1 (en) | 2002-05-10 | 2011-10-26 | Purdue Research Foundation | Epha2 agonistic monoclonal antibodies and methods of use thereof |
| EP1852441B1 (en) | 2002-09-24 | 2012-03-28 | The Burnham Institute | Agents that modulate EPH receptor activity |
| AU2003268345A1 (en) | 2002-09-24 | 2004-04-19 | The Burnham Institute | Novel agents that modulate eph receptor activity |
| CA2499816C (en) | 2002-09-27 | 2013-07-30 | Xencor, Inc. | Optimized fc variants and methods for their generation |
| WO2004029218A2 (en) | 2002-09-27 | 2004-04-08 | Incyte Corporation | Receptors and membrane-associated proteins |
| US7217797B2 (en) | 2002-10-15 | 2007-05-15 | Pdl Biopharma, Inc. | Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis |
| US20040253606A1 (en) | 2002-11-26 | 2004-12-16 | Protein Design Labs, Inc. | Methods of detecting soft tissue sarcoma, compositions and methods of screening for soft tissue sarcoma modulators |
| WO2004072266A2 (en) | 2003-02-13 | 2004-08-26 | Kalobios Inc. | Antibody affinity engineering by serial epitope-guided complementarity replacement |
| CA2525899C (en) | 2003-05-09 | 2016-03-08 | Diadexus, Inc. | Ovr110 antibody compositions and methods of use |
| KR20060034231A (ko) | 2003-06-06 | 2006-04-21 | 메디뮨 인코포레이티드 | 암의 진단, 치료 및 예방에 있어서의 ｅｐｈａ４ 및ｅｐｈａ４ 조정제의 용도 |
| US20050153923A1 (en) | 2003-12-04 | 2005-07-14 | Kinch Michael S. | Targeted drug delivery using EphA2 or EphA4 binding moieties |
| ES2414460T3 (es) | 2004-08-04 | 2013-07-19 | Amgen Inc. | Anticuerpos para Dkk-1 |
| AU2005277567A1 (en) | 2004-08-16 | 2006-03-02 | Medimmune, Llc | Integrin antagonists with enhanced antibody dependent cell-mediated cytotoxicity activity |
| CA2584804A1 (en) | 2004-10-21 | 2006-05-04 | The Penn State Research Foundation | Eph receptor tumor biomarkers |
| WO2006052409A2 (en) | 2004-10-23 | 2006-05-18 | Case Western Reserve University | Peptide and small molecule agonists of epha and their uses |
| US20060121042A1 (en) | 2004-10-27 | 2006-06-08 | Medimmune, Inc. | Modulation of antibody specificity by tailoring the affinity to cognate antigens |
| CA2621502A1 (en) | 2005-09-07 | 2007-03-15 | Medimmune, Inc. | Toxin conjugated eph receptor antibodies |
| US7807459B2 (en) | 2005-09-27 | 2010-10-05 | Reneuron, Inc. | EphA4-positive human adult pancreatic endocrine progenitor cells |
| US20070123448A1 (en) | 2005-11-23 | 2007-05-31 | The Hospital For Sick Children | Novel chemical entities affecting neuroblastoma tumor-initiating cells |
| JP2009531273A (ja) | 2006-02-28 | 2009-09-03 | オンコセラピー・サイエンス株式会社 | 抗ＥｐｈＡ４抗体のエフェクター機能を用いて細胞を障害する方法 |
| JP5167155B2 (ja) | 2006-03-09 | 2013-03-21 | ザ ボード オブ リージェンツ オブ ザ ユニバーシティー オブ テキサス システム | ペプチド結合に基づく多数の細胞株のプロファイリングに関連した組成物および方法 |
| US20080003210A1 (en) | 2006-03-13 | 2008-01-03 | Medimmune, Inc. | Non-human primate receptor tyrosine kinases |
| US7951918B2 (en) | 2006-03-17 | 2011-05-31 | Biogen Idec Ma Inc. | Stabilized polypeptide compositions |
| MX2008015492A (es) | 2006-06-06 | 2009-02-12 | Univ Tennessee Res Foundation | Composiciones enriquecidas en celulas madre neoplasicas y metodos que las contienen. |
| CN105837690A (zh) | 2006-06-12 | 2016-08-10 | 新兴产品开发西雅图有限公司 | 具有效应功能的单链多价结合蛋白 |
| CN101622276B (zh) * | 2006-07-18 | 2015-04-22 | 赛诺菲-安万特 | 用于治疗癌症的抗epha2的拮抗抗体 |
| US20100297140A1 (en) * | 2006-08-31 | 2010-11-25 | A.C.N 135 493 391 Pty Ltd As Trustee For Conca Unit Trust | Uses of antibodies |
| PT3207941T (pt) | 2006-09-07 | 2020-04-02 | Scott & White Memorial Hospital | Métodos e composições baseados em conjugados de toxina diftérica-interleucina-3 |
| AU2007331672A1 (en) | 2006-12-15 | 2008-06-19 | Ablynx N.V. | Amino acid sequences that modulate the interaction between cells of the immune system |
| CN101855339A (zh) | 2007-01-22 | 2010-10-06 | 雷文生物技术公司 | 人类癌症干细胞 |
| PT3199180T (pt) * | 2007-03-08 | 2022-04-01 | Univ Monash | Anticorpos epha3 para o tratamento de tumores sólidos |
| WO2009012357A2 (en) | 2007-07-17 | 2009-01-22 | The General Hospital Corporation | Methods to identify and enrich for populations of ovarian cancer stem cells and somatic ovarian stem cells and uses thereof |
| EP2022848A1 (en) | 2007-08-10 | 2009-02-11 | Hubrecht Institut | A method for identifying, expanding, and removing adult stem cells and cancer stem cells |
| CN101842116A (zh) | 2007-08-28 | 2010-09-22 | 比奥根艾迪克Ma公司 | 结合igf-1r多个表位的组合物 |
| EP2348052A3 (en) * | 2007-09-17 | 2011-10-26 | The Regents of The University of California | Internalizing human monoclonal antibodies targeting prostate cancer cells in situ |
| WO2009043051A2 (en) | 2007-09-27 | 2009-04-02 | Biogen Idec Ma Inc. | Cd23 binding molecules and methods of use thereof |
| US20110091473A1 (en) * | 2007-10-22 | 2011-04-21 | Genmab A/S | Novel antibody therapies |
| US20100113415A1 (en) * | 2008-05-29 | 2010-05-06 | Rajapakse Hemaka A | Epha4 rtk inhibitors for treatment of neurological and neurodegenerative disorders and cancer |
| WO2010037134A2 (en) | 2008-09-29 | 2010-04-01 | Stemlifeline, Inc. | Multi-stage stem cell carcinogenesis |
| WO2010066835A2 (en) | 2008-12-10 | 2010-06-17 | Ablynx Nv | Eph receptor and ephrin ligand interaction |
| KR20110108390A (ko) | 2009-01-12 | 2011-10-05 | 신텔렉트 인코포레이티드 | 레이저로 매개된 박막 절개 및 세포 군체의 이동 |
| US20110020221A1 (en) | 2009-04-09 | 2011-01-27 | The Johns Hopkins University | Cancer stem cell expression patterns and compounds to target cancer stem cells |
| WO2010141974A1 (en) | 2009-06-10 | 2010-12-16 | The University Of Melbourne | Therapeutic applications |
| WO2013119964A2 (en) | 2012-02-08 | 2013-08-15 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| WO2012031280A2 (en) | 2010-09-03 | 2012-03-08 | Stem Centrx, Inc. | Identification and enrichment of cell subpopulations |
| US20130061342A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US20130061340A1 (en) | 2011-09-02 | 2013-03-07 | Stem Centrx, Inc. | Identification and Enrichment of Cell Subpopulations |
| US9778264B2 (en) | 2010-09-03 | 2017-10-03 | Abbvie Stemcentrx Llc | Identification and enrichment of cell subpopulations |
| EP2446895A1 (en) | 2010-10-01 | 2012-05-02 | Stemgen S.P.A. | EPH receptor expression in tumor stem cells |
| US20140302034A1 (en) | 2010-12-08 | 2014-10-09 | Stem Centrx, Inc. | Novel modulators and methods of use |
| PE20160674A1 (es) | 2013-08-28 | 2016-07-21 | Stemcentrx Inc | Metodos de conjugacion de anticuerpos especificos de sitio y composiciones |
| US20190209704A1 (en) | 2014-10-20 | 2019-07-11 | Igenica Biotherapeutics, Inc. | Novel antibody-drug conjugates and related compounds, compositions and methods of use |
| US11392902B2 (en) | 2017-06-06 | 2022-07-19 | United Parcel Service Of America, Inc. | Systems, methods, apparatuses and computer program products for providing notification of items for pickup and delivery |
-
2011
- 2011-12-07 US US13/995,086 patent/US20140302034A1/en not_active Abandoned
- 2011-12-07 CA CA2820885A patent/CA2820885A1/en not_active Abandoned
- 2011-12-07 CN CN201180065609.1A patent/CN103347538B/zh not_active Expired - Fee Related
- 2011-12-07 AR ARP110104586A patent/AR084208A1/es unknown
- 2011-12-07 BR BR112013014119A patent/BR112013014119A8/pt not_active Application Discontinuation
- 2011-12-07 SG SG2013044417A patent/SG191081A1/en unknown
- 2011-12-07 SG SG2013043039A patent/SG190990A1/en unknown
- 2011-12-07 NZ NZ611428A patent/NZ611428A/en not_active IP Right Cessation
- 2011-12-07 WO PCT/US2011/063831 patent/WO2012118547A1/en not_active Ceased
- 2011-12-07 TW TW100145222A patent/TWI585106B/zh not_active IP Right Cessation
- 2011-12-07 RU RU2013128444/10A patent/RU2592672C9/ru not_active IP Right Cessation
- 2011-12-07 AU AU2011360938A patent/AU2011360938B2/en not_active Ceased
- 2011-12-07 SG SG10201601792UA patent/SG10201601792UA/en unknown
- 2011-12-07 KR KR1020137017734A patent/KR20140031175A/ko not_active Abandoned
- 2011-12-07 MX MX2013006569A patent/MX356400B/es active IP Right Grant
- 2011-12-07 NZ NZ705008A patent/NZ705008A/en not_active IP Right Cessation
- 2011-12-07 CN CN201610633887.7A patent/CN106279415A/zh active Pending
- 2011-12-07 AU AU2011338425A patent/AU2011338425A1/en not_active Abandoned
- 2011-12-07 CA CA2819861A patent/CA2819861A1/en not_active Abandoned
- 2011-12-07 JP JP2013543326A patent/JP6279903B2/ja not_active Expired - Fee Related
- 2011-12-07 US US13/992,599 patent/US9320812B2/en not_active Expired - Fee Related
- 2011-12-07 EP EP11801934.8A patent/EP2648748A1/en not_active Withdrawn
- 2011-12-07 TW TW106101451A patent/TWI655210B/zh not_active IP Right Cessation
- 2011-12-07 PE PE2017000463A patent/PE20171143A1/es unknown
- 2011-12-07 EP EP11802250.8A patent/EP2648749A2/en not_active Withdrawn
- 2011-12-07 PH PH1/2013/501137A patent/PH12013501137A1/en unknown
- 2011-12-07 BR BR112013014321A patent/BR112013014321A2/pt not_active IP Right Cessation
- 2011-12-07 WO PCT/US2011/063834 patent/WO2012078813A2/en not_active Ceased
- 2011-12-07 NZ NZ728016A patent/NZ728016A/en not_active IP Right Cessation
- 2011-12-07 PE PE2013001372A patent/PE20140673A1/es active IP Right Grant
- 2011-12-07 RU RU2016123839A patent/RU2016123839A/ru not_active Application Discontinuation
-
2013
- 2013-06-07 CO CO13138765A patent/CO6821883A2/es active IP Right Grant
-
2016
- 2016-03-17 US US15/072,811 patent/US9969798B2/en not_active Expired - Fee Related
- 2016-03-17 US US15/072,930 patent/US9765136B2/en not_active Expired - Fee Related
- 2016-10-19 AU AU2016247113A patent/AU2016247113A1/en not_active Abandoned
-
2017
- 2017-06-16 PH PH12017501139A patent/PH12017501139A1/en unknown
- 2017-07-03 JP JP2017130334A patent/JP6491701B2/ja not_active Expired - Fee Related
-
2018
- 2018-04-18 US US15/956,213 patent/US20180237512A1/en not_active Abandoned
- 2018-10-18 AU AU2018250466A patent/AU2018250466A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2018008949A5 (enExample) | ||
| US11220551B2 (en) | CD133-binding agents and uses thereof | |
| US9975954B2 (en) | Anti-Axl antibodies | |
| JP2017535257A5 (enExample) | ||
| JP2019532056A5 (enExample) | ||
| Jain et al. | The development of a recombinant scFv monoclonal antibody targeting canine CD20 for use in comparative medicine | |
| JP2017537620A5 (enExample) | ||
| JP2019500020A5 (enExample) | ||
| JP2013544493A5 (enExample) | ||
| WO2015193430A1 (en) | Anti-axl antibodies | |
| JP2011505146A5 (enExample) | ||
| RU2013128444A (ru) | Новые модуляторы и способы их применения | |
| RU2009123409A (ru) | Новые антипролиферативные антитела | |
| CN115052896A (zh) | 抗ror1抗体和组合物 | |
| AU2017358359B2 (en) | Antibody binding specifically to CD66c and use thereof | |
| Dengl et al. | Engineered hapten‐binding antibody derivatives for modulation of pharmacokinetic properties of small molecules and targeted payload delivery | |
| JP2014515600A5 (enExample) | ||
| JP2018528759A5 (enExample) | ||
| AU2017352553A1 (en) | Anti-bag3 antibodies in combination with inhibitors of immune check-point for therapeutic use | |
| JPWO2019212965A5 (enExample) | ||
| WO2020247827A1 (en) | Antigen-binding protein constructs and uses thereof | |
| Zhou et al. | Elucidating the development, characterization, and antitumor potential of a novel humanized antibody against Trop2 | |
| JP7604452B2 (ja) | 結合メンバー | |
| TWI888704B (zh) | 抗ｃｄ７３之抗體及其應用 | |
| CN113330035A (zh) | 抗β1整合素人源化抗体以及包含其的用于治疗癌症的药学组合物 |